Literature DB >> 23441035

Reversible and tissue-specific activation of MAP kinase signaling by tamoxifen in Braf(V637)ER(T2) mice.

Oskar Ortiz1, Wolfgang Wurst, Ralf Kühn.   

Abstract

Deregulated MAP kinase (MAPK) signaling plays key roles in developmental and adult disease processes, but the experimental activation of MAPK is a currently unresolved task. For the reversible induction of MAPK signaling, we generated transgenic mice harboring a tamoxifen inducible BRAF(V637E)ER(T2) fusion protein. The expression of the inducible BRAF kinase can be directed by Cre/loxP-mediated recombination to selected cell types and enables the highly specific activation of MAPK signalling in vivo. We show that MAPK signaling can be transiently activated in the brain, liver, or kidney of Braf(V637E)ER(T2) mice by a single injection of tamoxifen. Braf(V637E)ER(T2) mice provide a new versatile tool to study disease mechanisms elicited by MAPK activation, complementing gene knockout technology that is restricted to the analysis of loss-of-function phenotypes.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23441035     DOI: 10.1002/dvg.22386

Source DB:  PubMed          Journal:  Genesis        ISSN: 1526-954X            Impact factor:   2.487


  3 in total

1.  Development of an intein-mediated split-Cas9 system for gene therapy.

Authors:  Dong-Jiunn Jeffery Truong; Karin Kühner; Ralf Kühn; Stanislas Werfel; Stefan Engelhardt; Wolfgang Wurst; Oskar Ortiz
Journal:  Nucleic Acids Res       Date:  2015-06-16       Impact factor: 16.971

2.  Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing.

Authors:  Jia Lu; Chen Zhao; Yingze Zhao; Jingfang Zhang; Yue Zhang; Li Chen; Qiyuan Han; Yue Ying; Shuai Peng; Runna Ai; Yu Wang
Journal:  Nucleic Acids Res       Date:  2018-03-16       Impact factor: 16.971

3.  HIT-Cas9: A CRISPR/Cas9 Genome-Editing Device under Tight and Effective Drug Control.

Authors:  Chen Zhao; Yingze Zhao; Jingfang Zhang; Jia Lu; Li Chen; Yue Zhang; Yue Ying; Junjun Xu; Shixian Wei; Yu Wang
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-01       Impact factor: 8.886

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.